Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 27, 2025 08:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics to Participate in Two September Healthcare Conferences
August 07, 2025 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 29, 2025 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of IT
July 28, 2025 08:45 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Leadership Transition

Aclaris Therapeutics Announces Scientific Leadership Transition
June 30, 2025 09:31 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
June 26, 2025 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
June 23, 2025 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
June 02, 2025 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
May 28, 2025 09:20 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for...
May 09, 2025 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series